REG - GSK PLC - GSK Board changes

GSKAnnouncement

24/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220824:nRSX9882Wa&default-theme=true

RNS Number : 9882W  GSK PLC  24 August 2022

Issued: 24 August 2022, London UK - LSE announcement

 

GSK Board changes

 

·   Elizabeth (Liz) McKee Anderson to join the Board as Non-Executive
Director

·   Appointment follows announcement that Dr Laurie Glimcher will retire
from the Board in October 2022

 

 

 

GSK plc (LSE/NYSE: GSK) has today announced that Elizabeth (Liz) McKee
Anderson will join the Board of the Company as a Non-Executive Director with
effect from 1 September 2022.

 

Liz brings significant experience in commercial biopharmaceuticals and is a
seasoned biotech board member. She previously served as Worldwide Vice
President and commercial leader in infectious diseases and vaccines and also
for immunology and oncology at Janssen Pharmaceuticals, and as Vice President
and General Manager at Wyeth Vaccines. Liz is currently a Board member of;
BioMarin Pharmaceuticals, Revolution Medicines, Inc., Insmed, Inc., and Aro
Biotherapeutics Company. She was also previously a Board member of Bavarian
Nordic A/S and of Huntsworth Plc. Liz also serves on the Board of Trustees of
The Wistar Institute, a leading biomedical research organisation in the US.

 

Liz's appointment follows the announcement in July 2022, that Dr Laurie
Glimcher has advised the Company of her intention to retire from the Board on
13 October 2022 after over 5 years as a Non-Executive Director and designated
Scientific and Medical Expert.

 

Commenting on the changes, Sir Jonathan Symonds, Chair of GSK, said: "I would
like to express my sincere thanks to Laurie for her excellent contribution and
commitment to GSK over a number of years. Through her expertise in scientific
and medical innovation, and public health, Laurie has played a central role in
the development of GSK's current strategy and successful transition to a
focused biopharma company. We wish her well for the future."

 

"I am delighted to welcome Liz to GSK. Her significant experience in
commercial biopharmaceuticals, both operationally and at Board level, as well
as her deep understanding of the biotechnology sector will be invaluable to
GSK as we begin our next chapter as a 100% focused biopharma company."

 

Notes:

 

   1.   The appointment of Elizabeth McKee Anderson was made by the Board on
   the recommendation of the Nominations & Corporate Governance Committee.
   The Committee conducted an extensive search and selection process for this
   appointment, using an external search firm, which is a signatory of the
   Voluntary Code of Conduct for Executive Search Firms.  The external search
   firm provided a diverse list of candidates who were approached, evaluated and
   interviewed, against an agreed set of criteria aligned to the Board's target
   skills matrix.

   2.   The Board has determined that Elizabeth McKee Anderson is an
   independent Non-Executive Director in accordance with the UK Corporate
   Governance Code.

   3.   Ms McKee Anderson will receive the standard basic fee for a
   Non-Executive Director of £95,000 per annum. (Ms McKee Anderson will be
   required to build towards a share ownership requirement of GSK shares in
   accordance with the Company's shareholder approved Non-Executive remuneration
   policy).

   4.   Ms McKee Anderson has also been appointed a member of the Audit &
   Risk and Remuneration committees.

   5.   Ms McKee Anderson does not have a service contract. She has a letter of
   appointment which may be viewed by contacting the Company Secretary at the
   Company's registered office.

   6.   There are no further disclosures to be made in respect of Ms McKee
   Anderson's appointment under Listing Rule 9.6.13R.

   7.   As of 1 September 2022 the Board of GSK will comprise:

Sir Jonathan Symonds      Non-Executive Chair
   Emma Walmsley             Chief Executive Officer
   Iain Mackay               Chief Financial Officer
   Charles Bancroft          Senior Independent Non-Executive Director
   Elizabeth McKee Anderson  Independent Non-Executive Director
   Dr Hal Barron             Non-Executive Director
   Dr Anne Beal              Independent Non-Executive Director
   Dr Hal Dietz              Independent Non-Executive Director
   Dr Jesse Goodman          Independent Non-Executive Director
   Dr Laurie Glimcher*       Independent Non-Executive Director
   Urs Rohner                Independent Non-Executive Director
   Dr Vishal Sikka           Independent Non-Executive Director

 

*Retires from the Board on 13 October 2022.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com/company
(https://www.gsk.com/en-gb/company/)

 

 GSK enquiries
 Media:               Simon Moore      +44 (0) 20 8047 5502  (London)
                      Alison Hunt      +1 202 603 5003       (Washington DC)

 Investor Relations:  Nick Stone       +44 (0) 7717 618834   (London)
                      James Dodwell    +44 (0) 20 8047 2406  (London)
                      Mick Readey      +44 (0) 7990 339653   (London)
                      Josh Williams    +44 (0) 7385 415719   (London)
                      Jeff McLaughlin  +1 215 751 7002       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022
and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFSDTRIVFIF